Skip to content
Surf Wiki
Save to docs
general/autoantibodies

From Surf Wiki (app.surf) — the open knowledge base

Anti-Scl-70 antibodies

Anti-topoisomerase antibody


Anti-topoisomerase antibody

Anti-Scl-70 (also called anti-topoisomerase I after the type I topoisomerase target) is an anti-topoisomerase antibody-type of anti-nuclear autoantibodies, seen mainly in diffuse systemic scleroderma (with a sensitivity of 28–70%), but is also seen in 10–18% of cases of the more limited form of systemic scleroderma called CREST syndrome. Anti Scl-70 antibodies are associated with more severe scleroderma disease.

The etymology of scl-70 consists of an abbreviation of scleroderma and a 70 kD extractable immunoreactive fragment that can be obtained from the otherwise larger (100–105 kD) target topoisomerase antigen (called the SCL-70 Antigen) of the antibodies.

References

References

  1. (1986). "Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I". Chromosoma.
  2. (2007). "Robbins Basic Pathology". Saunders.
  3. (1989). "Marker antibodies in scleroderma and polymyositis: clinical associations". Clin. Rheumatol..
  4. [http://www.immunovision.com/products/product-10-12-2004_10-18-23.html Product Name: SCL-70 Antigen] {{Webarchive. link. (2006-03-19 at ImmunoVision.com, retrieved April 2011)
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

Want to explore this topic further?

Ask Mako anything about Anti-Scl-70 antibodies — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report